[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632684":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":28,"centralContacts":33,"locations":39,"responsibleParty":61,"collaborators":10,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":72,"maxAge":10,"enrollmentInfo":73,"targetDuration":76,"studyType":77,"phases":10,"briefSummary":78,"conditions":79,"keywords":84,"overallStatus":42,"whyStopped":10,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"Lithuanian University of Health Sciences","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Non-persistent PSA group",null,"Patients after radical prostatectomy with first postoperative prostate-specific antigen value of \\\u003C0.1 ng\u002Fml 4-8 weeks after radical prostatectomy.",[13],"Procedure: Radical Prostatectomy",{"label":15,"type":10,"description":16,"interventionNames":17},"Persistent PSA group","Patients after radical prostatectomy with first postoperative prostate-specific antigen value of ≥0.1 ng\u002Fml 4-8 weeks after radical prostatectomy.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"PROCEDURE","Radical Prostatectomy","Radical prostatectomy for the treatment of prostate cancer. Open retropubic, laparoscopic or robot-assisted.",[9,15],[25,26,27],"Robot-Assisted Radical Prostatectomy","Laparoscopic Radical Prostatectomy","Retropubic Radical Prostatectomy",[29],{"name":30,"affiliation":31,"role":32},"Daimantas Milonas, MD, PhD, Professor","Lietuvos sveikatos mokslų universitetas","PRINCIPAL_INVESTIGATOR",[34],{"name":35,"role":36,"phone":37,"phoneExt":10,"email":38},"Gustas Sasnauskas, MD","CONTACT","+37063605330","gustas.sas@gmail.com",[40],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Lithuanian University of Health Sciences Hospital Kaunas Clinics, Department of Urology","RECRUITING","Kaunas","Kauno","LT-50161","Lithuania","LT",{"type":49,"coordinates":50},"Point",[51,52],23.90909,54.90156,{"lat":52,"lon":51},[55,59],{"name":56,"role":36,"phone":57,"phoneExt":10,"email":58},"Mindaugas Jievaltas, MD, PhD, Professor","+37037326090","urologijos.klinika@kaunoklinikos.lt",{"name":60,"role":32,"phone":10,"phoneExt":10,"email":10},"Gustas Sasnauskas, MD, PhD-Candidate",{"type":32,"investigatorFullName":62,"investigatorTitle":63,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Gustas Sasnauskas","MD, PhD Candidate","100632684","prognostic-value-of-early-postoperative-prostate-specific-antigen-for-oncological-outcomes-after-radical-prostatectomy-100632684",false,"NCT07516886","Prognostic Value of Early Postoperative Prostate-Specific Antigen for Oncological Outcomes After Radical Prostatectomy","PPSARP","Inclusion Criteria:\n\n* Patient is an adult biological male.\n* Patient has morphologically confirmed and untreated prostate cancer.\n* Patient who will be treated with open, laparoscopic or robot-assisted laparoscopic radical prostatectomy.\n* Patient is informed about this observational study and has signed the informed consent form.\n\nExclusion Criteria:\n\n* Patient has radiologically of morphologically confirmed prostate cancer metastases before the operation.\n* Patient received neoadjuvant prostate cancer treatment.\n* Patient is set to receive adjuvant treatment.\n* Patient has any contraindications for the operation.","MALE","18 Years",{"count":74,"type":75},500,"ESTIMATED","10 Years","OBSERVATIONAL","This prospective observational study aims to evaluate the prognostic significance of early postoperative prostate-specific antigen (PSA) levels in patients undergoing radical prostatectomy for prostate cancer.\n\nNo investigational interventions will be performed. All diagnostic procedures, follow-up assessments, and treatments will be conducted in accordance with standard clinical practice and established prostate cancer management guidelines. Participation in the study will not influence treatment decisions.",[80,81,82,83,21],"Prostate Cancer (Post Prostatectomy)","Prostate Cancer (Adenocarcinoma)","Prostate Cancer (Diagnosis)","Prostate Specific Antigen",[85,86,87,88],"prostate cancer","persistent prostate-specific antigen","prostate-specific antigen","radical prostatectomy","2026-04-01",{"date":91,"type":92},"2026-04-08","ACTUAL",{"date":94,"type":92},"2024-01-22",{"date":96,"type":75},"2039-07",{"name":5,"class":6},1]